Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- 3 More Companies Temporarily Discontinue Marketing Generics Due to GMP Non-Compliance at South Korean Supplier
November 16, 2012
- Acquisitions Support Recovery in Leading Domestic Drug Makers’ Overseas Sales Ratio to 37%
November 15, 2012
- Shionogi, ViiV Obtain Favorable Results in 3rd PIII Clinical Trial for Dolutegravir
November 15, 2012
- Healthcare Sales Soar 4.4% with Expansion of Abilify in Japan: Otsuka HD
November 15, 2012
- OrphanPacific to Initiate New Business Model “Contract MAH for Overseas Pharma”
November 15, 2012
- Japan’s 25 Major Drug Makers Log Contrasting Domestic Biz Results on Varying New Product Performances
November 14, 2012
- RaQualia to Slim Down Its Organization Considering Spinning Off Non-Core Development Programs
November 14, 2012
- Towa: 1st Half Sales Up 16%, But Less-than Expected Benefits from Generic Name Prescriptions
November 14, 2012
- Gap between Oncology MRs and Doctors Should Be Closed: Mr Mitsuhashi of Merck Serono
November 13, 2012
- CMIC HD Forms Business Partnership with Japanese Subsidiary of Leading CSO in Europe
November 13, 2012
- Ethical Drug Sales Down 4.9% in September: Crecon Report
November 13, 2012
- Tsumura Postpones Targeted Launch for Kampo Medicine Under Development in US
November 13, 2012
- GeneDesign to Comprehensively Support Development of Nucleic Acid Medicines through New CMC Research Center: Mr Sato
November 13, 2012
- Sawai Makes Downward Revision in Full-Year Sales Forecast Despite Increases in Sales, Profits in 1st Half
November 12, 2012
- Alliance with Choseido to Increase Nihon Chouzai’s Generic Lineup to 470: President Mitsuhara
November 12, 2012
- Tsumura Aims at Sales of 123 Billion Yen in FY 2015, to Expand Kampo Market: New Mid-Term Management Plan
November 12, 2012
- Sawai Sells off All Shares of Kyorin HD Following End of Talks for Business Integration
November 12, 2012
- Kaken Aims for Approval of Japan’s 1st Topical Onychomycosis Treatment Efinaconazole Next Year
November 12, 2012
- Time Will Tell Whether Once-monthly Products Ultimately Dominate or Merely Provide Another Option in the BP Market
November 12, 2012
- Sales Increase 3.4% as Generics Make Large Gains: Kyorin HD
November 9, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…